GlobeNewsWire
05 Aug 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Firefly Neuroscience saw a 291% year-over-year increase in clinical assessments by TMS center customers using its Evoke platform. — Rapid adoption growth in a specific clinical segment suggests strong commercial traction and potential for near-term revenue acceleration.
+0.60Firefly maintains a proprietary database of over 200,000 EEG/ERP brain scans, which it claims is the world's largest standardized repository of its kind. — A large, proprietary dataset provides a competitive moat and improves the accuracy of their AI models, increasing long-term enterprise value.
+0.40The Evoke system is FDA 510(k)-cleared for diagnostic and treatment monitoring of conditions including depression, dementia, anxiety, and PTSD. — Regulatory clearance removes a primary barrier to entry and allows the company to legally market and scale its product in the U.S.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reported a nearly four-fold year-over-year increase in clinical assessments using its AI-powered platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
18m ago
